Corcept Therapeutics Announces Second Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Corcept Therapeutics Announces Second Quarter 2014 Financial Results and Provides Corporate Update

MENLO PARK, CA--(Marketwired - Aug 5, 2014) - Corcept Therapeutics Incorporated ( NASDAQ : CORT )

  • Revenue increases 33 percent from prior quarter on continued uptake of Korlym ® for the treatment of Cushing's syndrome
  • GAAP net loss narrows to $0.07 per share; non-GAAP net loss narrows to $0.05 per share
  • Company reiterates 2014 revenue guidance of $25-29 million
  • Trial for treatment of triple-negative breast cancer to generate results in 2015
  • Phase 1 clinical trial of next-generation selective GR antagonist starts this month

Corcept Therapeutics Incorporated ( NASDAQ : CORT ), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today reported its financial results for the quarter ended June 30, 2014. The company also provided an update on its clinical programs.

Second Quarter Financial Results and Reaffirmation of 2014 Revenue Guidance

  • Corcept recognized $5.9 million in net revenue for the second quarter of 2014 compared to $4.4 million in the first quarter, an increase of 33 percent. The company's net loss in the second quarter on a GAAP basis was $7.6 million, or $0.07 per share, compared to a net loss of $13.9 million, or $0.14 per share, in the first quarter.
  • In 2014, Corcept's net loss on a GAAP basis included significant non-cash expenses of $2.2 million in the second quarter and $2.4 million in the first quarter. Excluding these non-cash expenses, the company's net loss on a non-GAAP basis was $5.4 million, or $0.05 per share, for the second quarter of 2014 and $11.5 million, or $0.11 per share, for the first quarter.
  • As of June 30, 2014, the company held cash and cash equivalents of $34.0 million.
  • The company reaffirmed its 2014 full-year revenue guidance of $25-29 million.

"Our Cushing's syndrome business grew broadly last quarter," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "We continue to introduce new physicians to Korlym ® and, as they see the marked difference it makes in the lives of the first patients for whom they prescribe the drug, these physicians become more likely to prescribe the medicine to additional patients."

"At this June's Endocrine Society meeting we offered tangible evidence that Korlym works well. Results from the long-term extension of our pivotal Phase 3 SEISMIC study showed maintenance of key Korlym benefits. Investigators also presented a number of case studies showing the remarkable degree to which Korlym has benefited commercial patients treated independently of that study."

Clinical Pipeline Progress

"There is substantial evidence that glucocorticoid receptor (GR) antagonists, such as Korlym, may have utility in treating a variety of severe illnesses," said Dr. Belanoff. "This quarter we made significant progress in the development of both Korlym and our portfolio of proprietary next-generation GR antagonists: Our clinical trial of Korlym for the treatment of triple-negative breast cancer will generate results in 2015. We will begin a Phase 1 clinical trial of one new compound -- CORT 125134 -- in the next few weeks and will advance more compounds into clinical trials next year. We look forward to presenting the results of these studies."

Financial Results

For the second quarter of 2014, Corcept recognized net product revenue of $5.9 million. The company reported a net loss of $7.6 million, or $0.07 per share, for the second quarter of 2014 compared to a net loss of $11.9 million, or $0.12 per share, for the same period in 2013.

The net loss on a GAAP basis for the second quarter of 2014 and for the second quarter of 2013 included non-cash stock-based compensation expenses of $1.2 million and $1.3 million, respectively. In addition, the company recognized non-cash interest expense related to its capped royalty financing transaction of $935,000 in the second quarter of 2014 and $1.1 million in the same period in 2013. After adjusting for these non-cash expenses, the company's net loss on a non-GAAP basis was $5.4 million, or $0.05 per share, for the second quarter of 2014, compared to $9.5 million, or $0.10 per share, for the second quarter of 2013. A reconciliation of GAAP net loss to non-GAAP net loss is included below.

Operating expenses for the second quarter of 2014 were $12.4 million, compared to $12.7 million for the corresponding period in 2013.

  • Selling, general and administrative expenses in the second quarter declined to $8.0 million, compared to $8.2 million for the comparable period in 2013.
  • Research and development expenses in the second quarter were $4.3 million, compared to $4.5 million for the second quarter of 2013.

Corcept's cash balance as of June 30, 2014 was $34.0 million, compared to $54.9 million at December 31, 2013.

Conference Call

Corcept will hold a conference call on August 5, 2014, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss this announcement. To participate, dial 1-888-771-4371 from the United States or +1-847-585-4405 internationally approximately ten minutes before the start of the call. The passcode is 37738631.

A replay will be available through August 19, 2014 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The passcode is 37738631.

About Korlym ®

Korlym competitively blocks the glucocorticoid receptor type II (GR) to which cortisol normally binds, thereby inhibiting the effects of excess cortisol in Cushing's syndrome patients. In April 2012, Corcept made Korlym available as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym was the first FDA-approved treatment for that illness and the FDA has designated it as an Orphan Drug for that indication. Orphan Drug designation is a special status designed to encourage the development of medicines for rare diseases and conditions. Because Korlym is an Orphan Drug, Corcept will have marketing exclusivity for the approved indication in the United States until February 2019.

About Cushing's Syndrome

Endogenous Cushing's syndrome is caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol and is generated by tumors that produce cortisol or ACTH. Cushing's syndrome is an orphan indication that most commonly affects adults aged 20-50. An estimated 10-15 of every one million people are newly diagnosed with this syndrome each year, resulting in over 3,000 new patients annually in the United States. An estimated 20,000 patients in the United States have Cushing's syndrome. Symptoms vary, but most people have one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing's syndrome can affect every organ system in the body and can be lethal if not treated effectively.

About Triple-Negative Breast Cancer

Triple-negative breast cancer is a form of the disease in which the three receptors that fuel most breast cancer growth -- estrogen, progesterone and the HER-2/neu gene -- are not present. Because the tumor cells lack the necessary receptors, common treatments, such as hormone therapy and drugs that target estrogen, progesterone and HER-2, are ineffective. In 2013, approximately 40,000 women were diagnosed with triple-negative breast cancer. There is no FDA-approved treatment and neither a targeted treatment nor a preferred standard chemotherapy regimen for relapsed triple-negative breast cancer patients exists.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Korlym, a first generation competitive GR antagonist, is the company's first FDA-approved medication. The company has a Phase 1 trial of mifepristone for the treatment of triple-negative breast cancer and a portfolio of selective GR antagonists that competitively block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, psychiatric and oncologic disorders. It also holds composition of matter patents for its selective GR antagonists.

Non-GAAP Measures of Net Loss

To supplement Corcept's financial results presented on a GAAP basis, we use non-GAAP measures of net loss that exclude significant non-cash expenses related to stock-based compensation expense and the recognition of interest expense under our capped royalty financing transaction. We believe that this non-GAAP measure of net loss helps investors better evaluate the company's past financial performance and potential future results. Non-GAAP measures should not be considered in isolation or as a substitute for comparable GAAP accounting and investors should read them in conjunction with the company's financial statements prepared in accordance with GAAP. The non-GAAP measure of net loss we use may be different from, and not directly comparable to, similarly titled measures used by other companies.

Forward-Looking Statements

Statements made in this news release, other than statements of historical fact, are forward-looking statements. These forward-looking statements, including statements regarding anticipated future revenues, the timing of clinical trials and clinical trial results and the advancement of additional compounds, are subject to known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements, including the pace of Korlym's acceptance by physicians and patients, the reimbursement decisions of government or private insurers, the pace of enrollment in or the outcome of the company's phase 1 study of mifepristone in the treatment of triple-negative breast cancer and the phase 1 study of its next-generation selective GR antagonist, CORT 125134, the effects of rapid technological change and competition, the protections afforded by Korlym's Orphan Drug designation or by Corcept's other intellectual property rights, or the cost, pace and success of Corcept's other product development efforts. These and other risks are set forth in the company's SEC filings, all of which are available from the company's website ( http://www.corcept.com ) or from the SEC's website ( http://www.sec.gov ). Corcept disclaims any intention or duty to update any forward-looking statement made in this news release.

 
 
CORCEPT THERAPEUTICS INCORPORATED
CONDENSED BALANCE SHEETS
(in thousands)
 
    June 30, 2014   December 31, 2013
    (Unaudited)   (Note)
         
ASSETS:            
  Cash and cash equivalents   $ 33,974   $ 54,877
  Trade receivables, net     2,225     1,428
  Inventory     5,642     5,546
  Other assets     2,549     1,226
    Total assets   $ 44,390   $ 63,077
             
LIABILITIES AND STOCKHOLDERS' EQUITY:            
  Accounts payable   $ 2,595   $ 2,381
  Deferred revenue     44     25
  Long-term obligation     35,032     35,065
  Other liabilities     3,267     4,589
  Stockholders' equity     3,452     21,017
    Total liabilities and stockholders' equity   $ 44,390   $ 63,077
                 

Note: Derived from audited financial statements at that date.

   
   
   
CORCEPT THERAPEUTICS INCORPORATED  
CONDENSED STATEMENTS OF OPERATIONS  
(in thousands, except per share amounts)  
   
(Unaudited)  
   
    Three Months Ended June 30,     Six Months Ended June 30,  
             
    2014     2013     2014     2013  
                                 
Revenues:                                
  Product sales, net   $ 5,851     $ 1,891     $ 10,255     $ 3,608  
                                 
Operating expenses:                                
  Cost of sales     215       23       389       43  
  Research and development     4,252       4,491       11,537       8,748  
  Selling, general and administrative     7,965       8,160       17,769       16,544  
    Total operating expenses     12,432       12,674       29,695       25,335  
Loss from operations     (6,581 )     (10,783 )     (19,440 )     (21,727 )
                                 
Interest and other expense     (971 )     (1,114 )     (2,041 )     (2,254 )
    Net loss and comprehensive loss   $ (7,552 )   $ (11,897 )   $ (21,481 )   $ (23,981 )
                                 
Basic and diluted net loss per share   $ (0.07 )   $ (0.12 )   $ (0.21 )   $ (0.24 )
                                 
Shares used in computing basic and diluted net loss per share     100,980       99,814       100,751       99,814  
                                 
                                 
   
CORCEPT THERAPEUTICS INCORPORATED  
RECONCILIATION OF GAAP TO NON-GAAP NET LOSS  
(in thousands, except per share amounts)  
   
(Unaudited)  
   
    Three Months Ended June 30,     Six Months Ended June 30,  
                         
    2014     2013     2014     2013  
                         
GAAP net loss   $ (7,552 )   $ (11,897 )   $ (21,481 )   $ (23,981 )
                                 
Significant non-cash expenses:                                
  Stock-based compensation                                
    Research and development     169       157       331       305  
    Selling, general and administrative     1,057       1,108       2,272       2,270  
      Total stock-based compensation     1,226       1,265       2,603       2,575  
  Accretion of interest expense related to long-term obligation     935       1,092       1,979       2,207  
    Non-GAAP net loss   $ (5,391 )   $ (9,540 )   $ (16,899 )   $ (19,199 )
                                 
                                 
GAAP basic and diluted net loss per share   $ (0.07 )   $ (0.12 )   $ (0.21 )   $ (0.24 )
                                 
Non-GAAP basic and diluted net loss per share as adjusted for significant non-cash expenses   $ (0.05 )   $ (0.10 )   $ (0.17 )   $ (0.19 )
                                 
Shares used in computing basic and diluted net loss per share     100,980       99,814       100,751       99,814  

CONTACT: Charles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 Email Contact www.corcept.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 94

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 144

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Re-Decking or Rebuilding Starts Below the Deck Boards

Updated Category News Views 47

A weathered deck can fool the eye in both directions: ugly boards may sit atop solid framing, while a tidy surface can hide trouble where nobody bothers to look. That is the useful, sober point in Dawn Walsh's guidance for Knoxville homeowners. The decision is not really about whether the top boards look tired. It is about whether the bones underneath still deserve...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into Cumberland Heights Data Breach Issue

Updated Category News Views 81

Cumberland Heights Foundation took a hit back in 2024 when Federman & Sherwood launched an investigation into a serious data breach that compromised personal information. The foundation discovered unauthorized access to sensitive data on their Microsoft O365 platform, prompting immediate scrutiny of their security practices. The Breach Unpacked: What Went Down? This...

Continue Reading
The Remarkable Growth of Parker Hannifin Stock Over Two Decades

Updated Category News Views 195

Unveiling Parker Hannifin's 20-Year Growth Journey Parker Hannifin (NYSE: PH) has consistently outperformed market expectations over the past twenty years. This company's remarkable growth story is not just about numbers; it’s a narrative blending innovation, strategy, and resilience. With an average annual return of 15.52%, Parker Hannifin has shown an annualized...

Continue Reading
CoStar Group Earnings Preview: What to Expect This Quarter

Updated Category News Views 174

CoStar Group’s Earnings Report On The Horizon Here we are—a big date looming. CoStar Group (NASDAQ:CSGP) is all set to drop its quarterly earnings report on February 24, 2026. Basically, a lot of eyes are glued to this one. It feels like the calm before the storm, right? Investors want that sweet taste of surpassing estimates, not to mention some favorable guidance...

Continue Reading
Richardson's Strategic Acquisition: Pasta Business Expansion

Updated Category News Views 221

Richardson International Expands with Pasta Acquisition Richardson International Limited, through its US subsidiary Richardson (US) Holdings Limited, has taken a significant step in the food processing sector. The company has entered into a definitive agreement to acquire the pasta business of 8th Avenue Food & Provisions, Inc. This exciting development marks a noteworthy...

Continue Reading
Sandvik Reports Key Financial Metrics for Second Quarter

Updated Category News Views 192

Sandvik's Financial Performance Overview In a recent release, Sandvik Aktiebolag has shared its financial metrics from the second quarter, revealing significant developments in order intake and revenue growth. The company, known for its innovative engineering solutions, reported an order intake of SEK 32,206 million, displaying a slight decline compared to the previous...

Continue Reading